Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?

Eskazan Ahmet Emre; Tiribelli Mario

首页> 外文期刊>Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis >Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?

【24h】

Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?

机译：切换到第二代酪氨酸激酶抑制剂或增加的伊马替尼剂量在慢性髓性白血病患者中具有长期益处，在伊马替尼的前期反应下的次优应对症？

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis》 |2018年第2018期|共2页
作者
Eskazan Ahmet Emre; Tiribelli Mario;
展开▼
作者单位

Istanbul Univ Cerrahpasa Fac Med Dept Internal Med Div Hematol Istanbul Turkey;

Univ Udine Dept Med Area Div Hematol &

BMT Udine Italy;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib? [J] . Eskazan Ahmet Emre, Tiribelli Mario Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis . 2018,第期

机译：切换到第二代酪氨酸激酶抑制剂或增加的伊马替尼剂量在慢性髓性白血病患者中具有长期益处，在伊马替尼的前期反应下的次优应对症？
2. Comparative analyses of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic phase chronic myeloid leukemia following suboptimal molecular response to first-line imatinib [J] . Lee Sung-Eun, Choi Soo-Young, Kim Soo-Hyun, Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis . 2018,第期

机译：少量分子反应对第一线伊马替尼的慢性分子慢性骨髓白血病患者中尼洛涅布对高剂量伊替尼与持续标准剂量伊替尼的比较分析
3. Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia [J] . Hoffmann Verena S., Hasford Joerg, Deininger Michael, Journal of Cancer Research and Clinical Oncology . 2017,第7期

机译：对标准剂量伊马替尼的系统评价和荟萃分析与高剂量伊马替尼和第二代酪氨酸激酶抑制剂慢性骨髓性白血病
4. Combination effects of repetitive pulsed magnetic stimulation and tyrosine kinase inhibitor imatinib for chronic myeloid leukemia cell line TCC-S [C] . S. Yamaguchi, M. Sekino, Y. Sato, Intermag Conference . 2006

机译：重复脉冲磁刺激和酪氨酸激酶抑制剂慢性髓性白血病细胞系TCC-S的组合效应
5. Influences on physician recommendation for imatinib mesylate in chronic phase chronic myeloid leukemia patients. [D] . Iyer, Shrividya Sethuraman. 2003

机译：对慢性期慢性粒细胞白血病患者甲磺酸伊马替尼的医师推荐的影响。
6. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10 of BCR-ABL/ABL ratio at 3 months [O] . Luis-Felipe Casado, José-Valentín García-Gutiérrez, Isabel Massagué, 2015

机译：改用第二代酪氨酸激酶抑制剂可改善一线伊马替尼治疗的慢性粒细胞白血病患者的反应和预后在3个月时其BCR-ABL / ABL比率超过10％
7. The Achievement of a 3-Month Complete Cytogenetic Response to Second-Generation Tyrosine Kinase Inhibitors Predicts Survival in Patients With Chronic Phase Chronic Myeloid Leukemia After Imatinib Failure [O] . Elias Jabbour, Hagop Kantarjian, Hady Ghanem, 2013

机译：对二代酪氨酸激酶抑制剂的3个月全组细胞遗传学反应的成就预测伊替尼酸慢性期慢性骨髓白血病患者的存活率

Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?

著录项

相似文献

相关主题

期刊订阅